A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC — StellaPhase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Trial locations(15 sites)
Australia
Liverpool Cancer Therapy Centre, Liverpool, New South Wales Macquarie University Hospital (MUH), Macquarie Park, New South Wales Scientia Clinical Research, Randwick, New South Wales Greenslopes Private Hospital - Cyril Gilbert Cancer Centre, Greenslopes, Queensland The Queen Elizabeth Hospital (TQEH), Woodville South, South Australia Last updated November 2025